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Summary. As many as 100,000 new cases of brain 
tumor are diagnosed each year in the United States. 
About half of these are primary gliomas and the 
remaining half are metastatic tumors and non-glial 
primary tumors. Currently, gliomas are classified based 
on phenotypic characteristics. Recent progress in the 
elucidation of genetic alterations found in gliomas have 
raised the exciting possibility of using genetic and 
molecular analyses to resolve some of the problematic 
issues currently associated with the histological 
approach to glioma classification. Recently, 
immunohistochemical studies using novel proliferation 
markers have significantly advanced the assessment of 
tumor growth potential and the grading criteria of some 
tumor subtypes. Preliminary studies using cDNA array 
technologies suggest that the profiling of gene 
expression patterns may provide a novel and meaningful 
approach to glioma classification and subclassification. 
Furthermore, cDNA array technologies may also be used 
to identify candidate genes involved in glioma tumor 
development, invasion, and progression. This review 
summarizes current glioma classification schemes that 
are based on histopathological characteristics and 
discusses the potential for using cDNA array technology 
in the molecular classification of gliomas. 
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Introduction 
Gliomas are the most common malignant primary 
brain tumors. They are derived from neuroepithelial cells 
and are extremely diverse with respect to location, 
morphology, differentiation, and response to therapy. 
They can be divided into two major lineages: astrocytic 
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tumors and oligodendrogliomas. Recently, the Central 
Brain Tumor Registry of the United States obtained 5 
years of incidence data (1990-1994). Among the primary 
brain tumors, a significant percentage of gliomas (>40%) 
were reported. An estimated 13,300 deaths in 1998 were 
attributed to primary malignant brain tumors (CBTRUS, 
1998). 
Diagnosis of tumors is conventionally achieved by 
assigning a presumed cell of origin and grade based 
largely on morphological criteria, such as the size, shape 
and pleomorphism of the tumor cells, the presence or 
absence of mitotic figures, vascular proliferation and 
necrosis, and pattern recognition of various architectural 
features that are traditionally associated with a given 
tumor type. However, accurate diagnosis is often 
problematic because the histologic features of most 
gliomas are heterogeneous and agreement on consensus 
criteria for the diagnosis and, particularly, the grading, of 
several glioma subtypes has been difficult to achieve. 
Lack of consensus on objective grading and 
classification criteria breeds subjectivity in diagnosis. A 
more objective classification system has long been 
needed to augment and complement the traditional 
histopathological approach. 
Recent developments in immunohistochemical 
techniques have allowed a more accurate assessment of 
proliferation indices, and early attempts to incorporate 
these into glioma grading systems have been made 
(Fuller and Burger, 1996a). Historically, a number of 
markers have been employed, including: (1) Ki-67, a 
nuclear nonhistone protein that is expressed by actively 
dividing cells, (2) proliferating cell nuclear antigen 
(PCNAIcyclin), an auxiliary protein of DNA polymerase 
6, and (3) bromodeoxyuridine (BrdU), a thymidine 
analogue that is incorporated into DNA during the S 
phase of the cell cycle (Vandenberg, 1992; Fuller, 1996a; 
Cavalla and Schiffer, 1997). The currently preferred and 
most widely used marker is  that detected by the 
monoclonal antibody MIB-1, which recognizes an 
epitope on the Ki-67 antigen. The principal advantage of 
this marker over the earlier Ki-67 monoclonal antibody 










